How to Track Patient Progress and Compliance for Substance Abuse Treatment in 2026

Tracking patient progress in substance use disorder treatment is harder than it looks on paper. You are juggling six ASAM dimensions per patient, a drug screen schedule that changes by level of care, group attendance across multiple modalities, MAT dosing that has to be reconciled daily, and outcomes that payers want documented at 30, 60, 90, and 180 days post-discharge. Miss a step-down criterion and a utilization reviewer denies the next week of authorization. Miss an MAT dose pattern and a patient walks out of treatment. Miss the 90-day outcome call and your reaccreditation file has a hole in it. The clinics that handle this well are not working harder — they are working off a structured tracking system that maps every patient to ASAM dimensions, trends drug screens automatically, auto-logs group attendance, flags MAT compliance gaps in real time, and queues outcomes follow-ups before anyone has to remember them. This guide is the procedural walkthrough for setting that up.

Before we get into steps, here is the goal state you are building toward. Every active patient has a current ASAM Criteria assessment with all six dimensions scored and dated. Drug screen results are trended over time on the chart, not stored as loose PDFs. Group attendance is auto-logged when a patient checks into a session, with participation quality captured in a structured field rather than a free-text note. MAT compliance — Suboxone, methadone, naltrexone, or whatever the patient is on — is tracked dose-by-dose, with missed doses flagged within 24 hours so a counselor can intervene. Level-of-care transitions (detox to residential, residential to PHP, PHP to IOP, IOP to OP) have documented criteria in the chart, not just a clinician's recollection. And outcomes are captured at 30, 60, 90, and 180 days post-discharge, with structured fields for sobriety status, employment, housing, legal involvement, and family functioning. If your current setup misses more than two of those, you have visible work ahead. The steps below are the shortest path there.

The ASAM Criteria are the spine of SUD treatment planning. If your tracking does not start here, nothing downstream will hold together. Every active patient should have a current assessment scored across all six dimensions:

Dimension 1 — Acute Intoxication and Withdrawal Potential. Current substance use, withdrawal severity, history of complicated withdrawal (seizures, DTs). Document withdrawal scale scores (CIWA for alcohol, COWS for opioids) and date them.

Dimension 2 — Biomedical Conditions and Complications. Liver disease, HIV, hepatitis C, pregnancy, chronic pain, cardiac issues, diabetes. List each with treatment status and the prescriber managing it.

Dimension 3 — Emotional, Behavioral, or Cognitive Conditions. Co-occurring depression, anxiety, PTSD, bipolar, psychosis, suicidal ideation. Document current diagnoses, medications, and the psychiatrist or PMHNP managing care.

Dimension 4 — Readiness to Change. Stage of change (precontemplation through maintenance), motivation level, treatment goals in the patient's own words. This dimension drives engagement strategy and matters for level-of-care decisions.

Dimension 5 — Relapse, Continued Use, or Continued Problem Potential. History of relapse, triggers, time since last use, prior treatment episodes and outcomes. The honest answer here often determines whether a patient needs residential versus IOP.

Dimension 6 — Recovery Environment. Housing stability, employment, social support, exposure to use in the home or workplace, transportation. A patient with strong dimensions 1-5 and a chaotic dimension 6 is at high risk in outpatient care.

Reassess at every level-of-care transition and at minimum every 30 days while in active treatment. Date the assessment, attribute it to the clinician, and lock it in the chart so utilization reviewers can see the timeline.

Once dimensions are scored, the next question is always: what level of care does this patient need, and what triggers a transition? Document explicit criteria for each pathway transition so step-downs and step-ups are clinical decisions, not scheduling decisions.

Detox to Residential. Withdrawal complete or stabilized (CIWA below 10 sustained, COWS below 12 sustained), no acute medical issues requiring inpatient management, patient willing and able to engage in residential programming. Document the withdrawal trend and the medical clearance.

Residential to PHP. ASAM Dimensions 1 and 2 stable, Dimension 3 manageable in a non-residential setting, recovery environment supportive enough for nights and weekends off-site, patient demonstrating engagement and readiness. Common minimum stay is 14-30 days residential before PHP step-down, but it is clinical, not calendar-driven.

PHP to IOP. Patient stable across dimensions, work or school reintegration appropriate, recovery environment continues to support, drug screens consistently negative for the substance of concern. PHP is typically 5-6 days/week of programming; IOP drops to 3 days/week.

IOP to OP. 30-90 days of consistent attendance, negative drug screens, established sober supports outside treatment, MAT dosing stable if applicable. OP weekly check-ins continue but the structured group programming ends.

Step-up triggers (any direction). Positive drug screen, missed group sessions in pattern, MAT non-adherence, acute mental health decompensation, loss of housing or employment. Step-ups are not failures — they are the system working. Document the trigger and the clinical reasoning in the same place you document step-downs.

Drug screens are the most visible objective measure of treatment response, and the most commonly mishandled. The two failures: paper logs that nobody trends, and PDFs uploaded to the chart but never extracted into structured fields. Either way, you cannot answer the basic question — "is this patient's screen pattern improving or worsening?" — without manually flipping through the chart.

Set up screening cadence by level of care. Detox: every 24-48 hours during admission. Residential: 2-3 times weekly, randomized. PHP: 2 times weekly minimum. IOP: weekly randomized. OP: every 2-4 weeks based on phase. Document the scheduled cadence in the patient's plan, then track actual collections against it — gaps in collection often correlate with relapse risk.

When results come back from your toxicology lab (LabCorp, Quest, USDTL, or a local POCT vendor), they should land directly in the chart as structured fields per analyte, not as a single PDF blob. That way the chart shows a trend line: the alcohol metabolite EtG declining over 60 days, the cocaine metabolite spiking on a Monday after a weekend pass, the buprenorphine present at expected levels confirming MAT adherence. Any positive result should auto-trigger a clinical review task — counselor reviews within 24 hours, contact with patient documented, plan update or level-of-care reconsideration if pattern emerges.

For compliance, retain results per state board and 42 CFR Part 2 requirements (typically 7+ years for adult records). For utilization review, payers increasingly want the screen trend in the concurrent review packet, not just the most recent result.

Group programming is the bulk of contact hours in PHP and IOP, and group attendance is one of the first things payers ask about during concurrent review. If a patient is authorized for 5 days of PHP and only attended 3 last week, the next authorization request needs to explain that — and you need to know about the absences before the reviewer does.

Auto-log attendance at session check-in. The cleanest way: a kiosk or staff-facilitated check-in that timestamps the patient into the session record. End-of-session, mark each attendee present, late, or left early, with a participation rating (engaged, observing, disruptive). For process groups, capture a brief structured note on themes — not a full SOAP note, but enough to show clinical content. For didactic groups, the curriculum topic and the patient's engagement level is usually sufficient.

Differentiate group types in the schedule and the attendance record: process group, psychoeducation, relapse prevention, family group, MAT support group, mutual help (AA/NA/SMART) integration. Payers want to see modality variety, and clinicians want to see whether a patient is engaging differently across types — a patient who attends every didactic but skips every process group is telling you something.

Absences should auto-trigger outreach. Pattern of two consecutive missed groups, a missed group plus a missed individual session, or three absences in a week — any of these should generate a counselor task within 24 hours: phone call, documented in the chart, with a brief plan (was patient ill, transportation issue, ambivalence, relapse risk). This single workflow probably has more impact on retention than any clinical intervention you can layer on top of treatment.

Medication-assisted treatment changes the math on long-term outcomes for opioid use disorder and alcohol use disorder. It also adds a tracking layer that, done badly, becomes a chart-flipping nightmare. Done well, it is a daily workflow that catches gaps before they become relapses.

Buprenorphine/naloxone (Suboxone, Zubsolv). Document the prescription, dosage, schedule, and prescribing provider. Track each dose for office-administered or observed dosing. For take-home prescriptions, track refill dates and pharmacy fills against expected. Drug screens should confirm buprenorphine present and norbuprenorphine in the expected ratio — unexpected ratios can indicate diversion or non-adherence. PDMP checks at the cadence required by your state, with the result documented in the chart.

Methadone. Daily observed dosing in the OTP, with each dose timestamped and witnessed. Take-home phases (1 through 6) with documented criteria for each advancement. Missed doses generate same-day clinical review. Drug screens, attendance, and observed behavior all factor into take-home decisions.

Naltrexone (oral and Vivitrol). For oral, daily medication adherence is largely self-report — track in concert with screens and clinical signals. For Vivitrol, track injection date, site, lot number, next due date. Missed injection triggers immediate clinical follow-up — the protective effect ends within 28 days.

Missed dose patterns matter more than single missed doses. One missed buprenorphine fill is worth a phone call. Three missed fills in 90 days is a level-of-care conversation. Build the pattern recognition into the system rather than relying on a counselor to remember the last missed dose three months ago. A good MAT dashboard for each patient shows: last dose, pattern of missed doses, next refill due, and PDMP last checked.

Outcomes data is the single highest-leverage asset a treatment program produces over time. It tells you whether your model works, which patient profiles do best, what the relapse curve looks like for your population, and — increasingly — what your reimbursement rate will be from value-based payers. Most programs do not capture it consistently. The ones that do have a structural advantage in marketing, accreditation, and contract negotiation.

Schedule outcomes follow-ups at four intervals post-discharge: 30 days, 60 days, 90 days, and 180 days. The 30-day call catches early relapse and re-engagement opportunities. The 90-day call aligns with most accreditation outcomes reporting requirements. The 180-day check-in correlates with sustained recovery and is increasingly what payers want for outcome-based contracts.

Use a structured outcomes assessment, not a free-text "how are you doing" note. Capture:

- Sobriety status. Self-reported abstinence, number of use episodes since discharge, last use date, substance(s) used. Where possible, a confirmatory drug screen at the 90-day in-person follow-up. - Employment. Working full-time, part-time, in school, looking, unable. Income range if patient will share. - Housing. Stable independent housing, sober living, family, homeless or unstable. Address change since discharge. - Legal status. Any new charges, pending court matters, probation/parole compliance. - Family and social. Relationship with primary supports — improved, same, worse. Active in mutual help, sponsor relationship if applicable. - MAT continuation. If discharged on MAT, current adherence and prescribing provider. This is one of the strongest predictors of sustained recovery.

No-contacts at follow-up are themselves a data point. If a patient is unreachable at 30 days, that is a relapse risk signal — escalate the outreach (alternate phone, emergency contact, sober support contact if patient consented). Track the contact rate as a program metric; programs with lower-than-50% contact rates at 90 days have a structural retention problem in their discharge planning.

These are the patterns we see most often in programs that struggle with progress tracking:

- No concurrent ASAM mapping. Initial assessment is scored, then dimensions never reappear in the chart. Reassessment happens only when a level-of-care change is already triggered, not as the trigger itself. - Paper drug screen logs. Results live in a binder, get manually transcribed (poorly) into a weekly spreadsheet, and never trend on the chart. Patterns that should be obvious are invisible. - Manual group attendance. Counselor signs in 12 patients on a sheet, sheet gets entered later, attendance for utilization review pulled from memory or estimated. Discrepancies between attendance records and clinical notes show up at audit. - MAT tracked separately from clinical. Dosing handled in pharmacy or MAT-specific software, clinical handled in primary EHR, no unified view of adherence plus screens plus group attendance. Counselors miss patterns because the data lives in three places. - No outcomes follow-up at all. Discharge happens, chart closes, no scheduled outreach. Program has no idea what its actual outcomes are and reverts to anecdote in marketing and accreditation. - Outcomes captured but unstructured. A counselor calls at 90 days, writes a paragraph in a free-text note. Data is there in narrative form but unanalyzable across patients. The aggregate picture stays invisible. - No alerts on missed doses or absences. Detection happens at the next clinical session, not in real time. A patient who missed three days of groups and two MAT doses is reviewed on Friday at the team meeting, by which point they have stopped answering the phone.

Deelo's Practice app is built around the workflow above for SUD programs. ASAM-aligned assessment templates score Dimensions 1-6 with date and clinician attribution, and reassessments populate a timeline view so utilization reviewers see the trend, not just the most recent score. Drug screen results from your tox lab feed into structured per-analyte fields, with trended graphs at the patient level and program level. Group attendance auto-logs at check-in with a structured participation field, and absence patterns auto-trigger counselor outreach tasks within 24 hours. MAT compliance is tracked dose-by-dose for buprenorphine, methadone, and naltrexone, with PDMP check reminders and missed-dose flags. Level-of-care transitions are documented with required ASAM criteria captured at the transition, so the chart explains every step-down and step-up. Outcomes follow-ups at 30/60/90/180 days are queued automatically at discharge, with a structured assessment for sobriety, employment, housing, legal, family, and MAT continuation. Pricing starts at $19/seat for Starter and goes up to $69/seat for Enterprise, with the billing automatically scaling with annual contracts. Smaller programs typically run on Starter or Business; larger multi-site programs and those with custom integration needs run on Enterprise.